Curated research links

A small molecule inhibitor of NNMT for metabolic disorders

Preclinical characterization of an NNMT inhibitor in diet-induced obesity (related to 5-Amino-1MQ pharmacology).

Stable gastric pentadecapeptide BPC 157 and wound healing

Review summarizing BPC-157 preclinical wound-healing and tissue-protection literature.

BPC-157 accelerates Achilles tendon healing in rats

Original rat Achilles transection study reporting accelerated tendon healing.

Cerebrolysin for acute ischaemic stroke — Cochrane systematic review

Cochrane assessment concluding insufficient evidence to determine effect on death or dependency in stroke.

Prolonged stimulation of GH and IGF-1 by CJC-1295, a long-acting GHRH analog

Clinical pharmacology of CJC-1295 DAC demonstrating extended GH/IGF-1 elevation in healthy adults.

Regenerative and protective actions of the GHK-Cu peptide

Comprehensive review of GHK-Cu — a common constituent of KLOW and GLO blends.

Larazotide acetate for persistent celiac symptoms (CeD-PRO)

Phase 2b trial of larazotide acetate — a constituent listed in some GLO formulations.

Ipamorelin, the first selective growth hormone secretagogue

Original characterization of ipamorelin's selectivity versus earlier GHS peptides.

Regenerative and protective actions of the GHK-Cu peptide

Comprehensive review of GHK-Cu — a common constituent of KLOW and GLO blends.

The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis

Original description of MOTS-c and its effects on insulin sensitivity in rodent models.

Therapeutic potential of NAD-boosting molecules: the in vivo evidence

Review of NAD+ and precursor pharmacology — the best starting point for NAD+/NR/NMN biology.

Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6)

Phase 3b cardiovascular outcomes trial — first large CV benefit signal for semaglutide.

Once-weekly semaglutide in adults with overweight or obesity (STEP 1)

Pivotal Phase 3 weight-management trial — 14.9% mean weight reduction at 68 weeks.

Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)

Extended CV benefit of semaglutide beyond diabetes, in adults with overweight/obesity.

Semax, an analog of ACTH(4-10), modulates BDNF in rat basal forebrain

Mechanism study linking Semax to BDNF expression changes in rat brain regions.

Sermorelin: a better approach to management of adult-onset GH insufficiency

Review of sermorelin pharmacology and historical clinical use.

Thymosin β4: actin-sequestering protein moonlights to repair injured tissues

Foundational review of thymosin β4 biology — the parent protein of the TB-500 fragment.

Tirzepatide versus semaglutide in type 2 diabetes (SURPASS-2)

Head-to-head Phase 3 showing larger A1C and weight reduction for tirzepatide.

Tirzepatide in adults with obesity (SURMOUNT-1)

~20% mean weight reduction at the highest dose — the largest Phase 3 weight-loss effect reported to date in a pharmacotherapy.

Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA)

Clinically meaningful apnea-hypopnea index reduction; expanded indication.